

Seq. Amndt F/#28
J 5.19.03

PATENT

Attorney Docket No.: 8830-170

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent application of
John Nelson, et al
Serial No.: 09/673,785
Filed: December 29, 2000
For: PEPTIDE FRAGMENTS OF MURINE
EPIDERMAL GROWTH FACTOR AS
LAMININ RECEPTOR TARGETS
Group Art Unit:
1653
Examiner:
Chih-Min Kam

RECEIVED
TECH. CENTER
1610/2900
MAY 16 PM 12:19

O.K.
to
enter
5/19/03

Amendment and Statement Under 37 C.F.R. 1.821

VIA HAND-DELIVERY

Commissioner for Patents
U.S. Patent and Trademark Office
7th Floor Reception
Crystal Mall One
1911 South Clark Place
Arlington, VA 22202

Sir:

This response to the Raw Sequence Listing Error Report, faxed from the U.S. Patent and Trademark Office on May 7, 2003. Please amend the application, without prejudice as follows:

In the specification:

Amend the specification by substituting the sequence listing with the sequence listing submitted herewith in paper and computer readable form. Support for the amendment is found in the specification. No new matter is added.

Statement Under 37 C.F.R. 1.821

The sequence listing information submitted herewith in computer readable form, is identical to the written sequence submitted herewith.

No new matter is added by this submission.

Respectfully submitted

JOHN NELSON, et al.

BY 

DANIEL A. MONACO

Reg. No. 30,480

DRINKER, BIDDLE & REATH LLP

One Logan Square

18th and Cherry Streets

Philadelphia, PA 19103-6996

(215) 988-3312

(215) 988-2757 – Fax

Attorney for the Applicants